Loading clinical trials...
Loading clinical trials...
A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy
Conditions
Interventions
Atezolizumab
Placebo
Locations
186
United States
Mayo Clinic- Scottsdale
Scottsdale, Arizona, United States
City of Hope National Medical Center
Duarte, California, United States
City of Hope, Antelope Valley
Lancaster, California, United States
UCLA Urology; Urology
Los Angeles, California, United States
University of California Irvine Medical Center
Orange, California, United States
City of Hope-South Pasadena
South Pasadena, California, United States
Start Date
January 3, 2017
Primary Completion Date
May 3, 2022
Completion Date
December 8, 2022
Last Updated
August 3, 2023
NCT05969860
NCT07227402
NCT04693377
NCT07117227
NCT06863311
NCT06500455
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions